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INTRODUCTION   
Obesity – a major health concern  
Obesity has turned up as one of the major health concerns in the 21st century and is one of 
the leading causes of preventable death (11). Obesity is a term applied to excess body 
weight with an abnormally high proportion of body fat. Thermodynamically speaking, 
imbalance between energy intake (feeding) and energy expenditure (physical activity) leads 
to obesity (113) . Development of obesity is, however, more complicated than that; 
sedentary life style, genetic factors, medical illness, microbiological aspects, social factors 
and neurobiological mechanisms are also involved (20; 33)   
 
Measurement of obesity. Obesity is commonly defined as body mass index (BMI, weight 
in kilograms divided by height in meters squared) of 30 kg/m2 or higher (92). BMI (or 
Quetelet index) was introduced between 1830 and 1850 by the Belgian polymath Adolphe 
Quetelet (60).  The classification of body weight according to WHO is as follows:  
 
BMI < 18.5 underweight 
BMI   18.5 - 24.9 normal weight   
BMI    25  - 29.9 overweight 
BMI    30  - 39.9 obese 






Although there is a correlation between obesity and cardiac disease, BMI is not a precise 
predictor of cardiovascular disease; absolute waist circumference or waist to hip ratio are 
more precise measures of central obesity and correlate better to health risks than BMI (69). 
 
 
Obesity, metabolic syndrome and insulin resistance. One of the obesity-associated 
health risks is development of metabolic syndrome. According to the WHO metabolic 
syndrome is characterized by the presence of central obesity, dyslipidemia (elevated 
triglycerides and decreased HDL cholesterol), impaired glucose tolerance or insulin 
resistance, type 2 diabetes and high blood pressure. In order to be diagnosed with metabolic 
syndrome an individual must be obese (BMI > 30 kg/m2) plus at least 2 additional risk 
factors, e.g. dyslipidemia and hypertension or dyslipidemia and impaired fasting glucose 
(127).  
 
More than 40 years ago Randle proposed that  fatty acid (FA) compete with glucose as an 
energy substrate in rat heart and diaphragm muscle, and speculated that increased fatty acid 
oxidation was responsible for the obesity-induced insulin resistance (118; 119). The 
proposed mechanism was that an increased FA uptake ultimately resulted in an increase in 
the intramitochondrial acetyl CoA/CoA and NADH/NAD+ ratios with subsequent 
inactivation of the pyruvate dehydrogenase. The high uptake of FA will lead to an increase 
in the intracellular concentration of citrate, leading to inhibition of phosphofruktokinase 
(Figure 1) (a rate limiting enzyme of glycolysis) and as a consequence, glucose 6 phosphate 
will accumulate and inhibit glucose uptake. Roden (122) also indicated an inhibitory effect 
of fatty acids on glucose transport and phosphorylation. More recently, it has been shown 
that an increase in the intracellular concentration of FA metabolites (diacylglycerol, fatty 




and inhibitory kappaB kinase (IKK), which ultimately block the insulin signaling pathway 
through functional inhibition of insulin receptor substrate -1 (IRS-1), (19; 67). Last, but not 
least, release of endocrine factors from adipose tissue, alone or in combination with other 






Diabetes and cardiac disease   
Diabetes mellitus is classified into type 1 and type 2 diabetes. Hereditary factors, diet and 
lifestyle, obesity and fat distribution, gestational predisposition and age are the main 
etiological factors of type 2 diabetes (123). Type1 diabetes is most often of genetic origin, 
although a combination of genetic predisposition with viral infection and autoimmune 
Fig. 1: Inhibition of glucose oxidation by increased FA supply. The uptake and oxidation of FA 
lead to citrate accumulation and inhibition of glucose utilization via inhibition of PFK. In 
addition FA inhibits glucose utilization via PDK-mediated inhibition of PDH via the PPARα 
pathway, as well as via inhibition of insulin signaling. PDH, pyruvate dehydrogenase; PFK, 
phosphofructokinase; IRS, insulin receptor substrate; PKB, protein kinase B; FA, fatty acid; 




disorders cannot be ruled out. The increased prevalance of type 2 diabetes worldwide is 
associated with significant increase in cardiovascular morbidity and mortality. Diabetes is 
presently estimated to affect more than 150 million patients worldwide, and this number is 
expected to double by 2025 (75; 143). Type 2 diabetic patients are more prone to develop 
angina and acute myocardial infarction, and the mortality rate is much higher among 
diabetics compared to non-diabetics suffering from acute myocardial infarction (57). The 
estimated four year survival rate is approximately 50% (37). There are two 
pathophysiological processes leading to type 2 diabetes-related cardiac complications: 
ischemic heart disease as a result of accelerated atherosclerosis and a specific diabetic 
cardiomyopathy, characterized initially as diastolic dysfunction which progresses to 
symptomatic heart failure (43). Although the pathogenesis of diabetic cardiomyopathy is 
multi-factorial and complex (Figure 2), metabolic disturbances related to hyper-lipidemia, 
hyper-glycemia and insulin resistance, as well as myocardial fibrosis, oxidative stress, and 







Myocardial substrate utilization  
The cardiac muscle needs a continuous supply of fuel in order to keep pumping. The daily 
ATP requirement of the heart is between 3.5 and 5 kg ATP (109).The heart demonstrates a 
great deal of flexibility with respect to its substrate selection, relying mainly on 
carbohydrates in the fed state, while lipids are the main source of energy during  fasting, as 
suggested by Bing in the early 1950s(17). Long chain FA and glucose are the predominant 
sources of energy for the myocardium during normal resting conditions (104), but lactate 
Fig. 2: Potential mechanisms for the development of diabetic cardiomyopathy: ROS, reactive 
oxygen species; TNFα, tumor necrosis factor alpha; IL-6, interleukin-6; AGE, advanced 




can also contribute to energy production, especially during periods of increased workload 
(38).  
 
Fatty acids. Oxidation of FA (unesterified, albumin-bound FA from adipose tissue or FA 
produced by lipoprotein lipase-mediated hydrolysis of triglyceride-rich lipoproteins) 
accounts for 60-70% of cardiac energy production. Fatty acid uptake in cardiac myocytes is 
mediated by FA transport proteins (FATP), FA translocase (FAT/CD36) and FA binding 
protein (FABP) (85). In the cytosol FA is activated by acyl-CoA synthase (ACS) to form 
acyl-CoA, which can either be transported  into the mitochondria for β-oxidation or 
undergo esterification to form intracellular TG (82). Before entering into the mitochondria 
acyl CoA is converted by carnitine palmitoyl transferase1 (CPT-I) to acyl carnitine (100) 
which in turn is reconverted to fatty acyl-CoA by CPT-II. Malonyl-CoA (produced by 
acetyl-CoA carboxylase) inhibits the activity of CPT1 and is considered a major inhibitor of 
FA oxidation (91). On the other hand, degradation of malonyl-CoA by malonyl CoA 
decarboxylase results in increased mitochondrial FA uptake. Once taken up by the 
mitochondria long chain fatty acyl CoA undergoes β-oxidation to yield acetyl CoA (Figure 
3) which is further oxidized in the krebs cycle to CO2, resulting in generation of NADH and 
FADH2 which ultimately provide reducing equivalents to the electron transport chain in 








Glucose. Glucose transport into cardiomyocytes is facilitated by GLUT1 and GLUT 4 (96) 
members of glucose transporter (GLUT) family. Myocardial glucose transport in basal 
conditions is mainly regulated by GLUT1 because of its more pronounced localization in 
the sarcolemma. GLUT4 is predominantly stored intracellularly, and its sarcolemmal 
translocation is mainly regulated by insulin-mediated phospho-inositol-3-kinase (PI3-K) 
pathway (85). However contraction induced myocardial glucose uptake is regulated by  
AMP-dependent kinase (AMPK)-mediated translocation of GLUT4 (28). Inside the cell, 
Fig. 3: Fatty acid and glucose uptake and metabolism. Intracellular FA uptake is mediated by 
passive diffusion or via transporters (CD36, FABP). Mitochondrial FA uptake is mediated by 
CPT-I and CPT-II, followed by entry into the β-oxidation, yielding acetyl-CoA and reducing 
equivalents which are channelled through the electron transport chain. Glucose is taken up by 
the transporters GLUT1/4, undergoes glycolysis to yield pyruvate, which thereafter is converted 
to acetyl CoA by PDH and further processed in the TCA cycle. FABP, Fatty acid binding 
protein; CPT-I, carnitine palmitoyl transferase 1; CPT-II, carnitine palmitoyl transferase-II; 
GLUT1, glucose transporter 1; GLUT4, (insulin-regulated) glucose transporter 4; PDH, 




glucose combines with a phosphate radical (glucose trapping) in the presence of hexokinase 
to form glucose 6-phosphate. Thereafter activated glucose 6-phosphate can enter into three 
different pathways: a catabolic pathway (glycolysis), glycogenesis or the pentose phosphate 
pathway. Pyruvate being the end product of glycolysis can be converted into acetyl CoA 
which enters into TCA cycle in the mitochondria. This key metabolic step is controlled by 
the pyruvate dehydrogenase (PDH) complex, which in turn is inhibited by pyruvate 
dehydrogenase kinase 4 (PDK4).    
    
Transcriptional regulation of myocardial metabolism  
Peroxisome proliferator activated receptors are ligand-activated transcription factors known 
to control many physiological functions, including glucose and lipid metabolism, cell 
growth and differentiation and vascular inflammatory processes (13; 47; 71). Thus, PPARs 
are important regulators of nutrient-gene interactions and potential targets for treatment and 
prevention of metabolic disturbances (124).  
 
PPAR isotypes. Peroxisome proliferator-activated receptors (PPARs) are subclassified into 
three types on the basis of their chromosomal localization and variation in tissue 
expression: PPARα, PPARβ/δ and PPARγ. These three isoforms were first discovered in 
Xenopus laevis (African clawed frog) (39), and later they have been identified in several 
mammalian species. Contrary to the PPARα and γ, the mammalian PPAR β isoform was 
only partly homologous to the Xenopus isoform, and for that reason the mammalian PPAR 
β was given an alternative name, PPAR δ (31). PPAR α is mainly expressed in liver, heart, 
kidney, skeletal muscle, endothelium, vascular smooth muscle, monocytes and 
macrophages (9). PPAR γ is expressed in white and brown adipose tissue, muscle, colon 




PPARs contain both a ligand-binding domain and a DNA-binding domain. Upon binding of 
ligand PPARs undergo conformational changes and form a heterodimer with the retinoid-X 
receptor (RXR, ligand-activated receptor) (72). Gene transcription is initiated following 
binding of the PPAR:RXR complex to the PPRE element in the enhancer site of the 
regulated gene (Figure 4). In addition, interaction of co-activators/co-repressors with the 
PPAR:RXR complex plays an important role in determining the physiological response to 
PPAR ligands. Finally, the activity of PPARs is regulated by their phosphorylation status, 
which is controlled by multiple kinase pathways, e.g. AMPK, JNK and mitogen-activated 
protein kinase (MAPK) (35).  
 
 
Fig. 4: Ligand-induced conformational change in PPARs results in heterodimer formation with 
RXR. This heterodimer, in association with co-activators, alters gene transcription by binding to 
specific PPREs in the promoter region of the target gene. PPAR, peroxisome proliferator-
activated receptor; PPRE, PPAR response element; RXR, retinoid X receptor (modified from 




PPAR ligands. In 1997 Krey and colleagues (77) screened several natural and synthetic 
candidate ligands (using a co-activator-dependent receptor ligand assay) and identified that 
naturally occurring FA (palmitic, oleic, linoleic and arachidonic acid) and their metabolites, 
as well as lipid-lowering drugs, were real ligands of the three PPAR subtypes. A number of 
synthetic ligands with different receptor specificity have become available over the last few 
years (Table 1).  
 
Table 1: PPAR ligands and their receptor specificity 
 
Ligand PPAR specificity Reference 
Fibrates α (76; 132) 
WY-14643 α (24) 
GW7647 α (148) 
GW9578 α (53) 
LY-518674 α (107) 
K-111 (previously called BM-17.0744) α (1; 93) 
Tetradecylthioacetic acid (TTA) pan (16; 88) 
Thiazoldinediones (glitazones) γ (128) 
GW 501516 δ (131) 
GW 0742 δ (24; 34) 
L-165041 δ (117) 
 
 
Diabetes-induced changes in myocardial fuel selection   
Type 2 diabetes is associated with dramatic changes in the concentration of energy 
substrates in the circulation, which in turn will influence cardiac metabolism. Plasma levels 
of both glucose and FA are increased in diabetes, and the rate of substrate uptake and 
oxidation in the cardiomyocytes are greatly influenced by the plasma supply. Impaired 
glucose uptake in the diabetic heart is a consequence of FA-induced inhibition of 
sarcolemmal GLUT4 expression (6). Besides, the increased FA supply will activate cardiac 
PPARα and promote expression of genes involved in FA uptake (84) and oxidation (144). 




of PFK-1 (49; 106) so that the heart depends mainly on FA as energy source. It has been 
suggested that the increased plasma availability of FA in diabetes results in increased 
myocardial FA uptake which might exceed the oxidative capacity of the heart (45). This 
imbalance between FA uptake and oxidation leads to accumulation of triacylglycerols, FA 
intermediates and ceramide within the cardiomyocyte, causing a state of lipotoxicity (150). 
Ceramide and diacylglycerol accumulation will further aggravate the condition by 
activating PKC isoforms, thereby increasing CD36-mediated FA uptake. In addition, these 
kinases induce inhibitory phosphorylations of IRS-1 resulting in insulin resistance (111). 
Studies have shown that there is a strong correlation between development of contractile 
dysfunction and myocardial lipotoxicity, which might be reversed by altering myocardial 
metabolism by use of PPAR ligands (26; 52; 110; 150). 
 
Prevention of myocardial lipotoxicity by administration of PPAR agonists 
PPARs are thought to play a vital role in preventing dyslipidemia by regulating transport, 
oxidation, storage and synthesis of FA (74). As mentioned above, PPARα is mainly 
expressed in tissues expressing high rates of mitochondrial FA oxidation, such as heart, 
liver and kidney (73), regulating transcription of genes involved in FA uptake and oxidation 
(146).   
PPARα: It has been shown that incubation of cardiomyocytes with PPARα ligands results 
in increased expression of PPARα target genes and increased FA oxidation (51; 140). The 
expression of PPARα target genes involved in cardiac FA uptake and oxidation pathways 
was increased in mice over-expressing PPARα (MHC-PPAR mice) (45). In addition, 
feedback induction of PPARα target genes, secondary to inhibition of fatty acid oxidative 
flux was lost in PPARα null mice (36). It is therefore generally accepted that increased FA 




when diabetic and obese mice were chronically treated with synthetic a PPARα ligands (K-
111), myocardial FA oxidation was reduced in perfused hearts from these animals (1; 2). 
This finding was surprising to many researchers in the field, but realizing that in vivo 
administration of the ligand also caused a profound stimulation of FA oxidation in the liver, 
implying an important mechanism for reduction of the plasma concentration of circulating 
lipids (FA and triglycerides), it became apparent that the reduction of myocardial FA 
oxidation in response to in vivo administration PPARα agonists could be a secondary effect 
of the reduced lipid burden.  
 
PPARγ: In contrast to PPARα, little is known about how PPARγ affects myocardial 
metabolism. However, experiments on type 2 diabetic mice performed in our own 
laboratory show that in vivo administration of rosiglitazone (an anti-diabetic drug in the 
thiazolidinedione class of drugs) results in a marked reduction of myocardial FA oxidation 
(with a simultaneous increase in glucose oxidation) in perfused hearts from these animals 
(65). Again, we have suggested that this response is secondary to the lipid-lowering action 
of the drug, in which PPARγ activation in adipose tissue leads to increased uptake and 
storage of FA, so that the adipose tissue serves as a sink for circulating FA.  
 
PPAR β/δ: Despite predominant expression of PPARβ/δ in cardiomyocytes (51), little is 
known about their role in the regulation of myocardial lipid metabolism. Cheng has 
however documented that PPARβ/δ  overexpression in cardiomyocytes, as well as 
treatment of cardiomyocytes with a highly specific PPARδ ligand (GW0742) was 
associated with elevation of FA oxidation genes (25). In support of this observation this 
author found that myocardial FA oxidation was decreased in a cardiomyocyte-restricted 




increased myocardial triglyceride content, indicating that PPARδ is involved in regulating 
myocardial substrate utilization.   
 
Anti-inflammatory properties of PPAR agonists 
Early evidence that PPARα is involved in mediating anti-inflammatory responses came 
from a study by Devchand et al. (32), in which it was documented that LTB4, a 
chemotactic agent of inflammation was more efficiently cleared from plasma of PPARα 
over-expressing mice, when compared with PPARα null mice. The postulated mechanism 
was that LTB-4, being a PPARα ligand itself, will result in activation of PPARα and induce 
LTB-4 catabolism in a feedback manner (32). Subsequent studies have documented anti-
inflammatory effects of PPARα via inhibition of various pro-inflammatory molecules, e.g. 
tissue factor (89; 105) and matrix metalloproteinase 9 ( MMP9) by interfering with NF-κB 
pathway (126). Recently PPARα has been shown to inhibit a pro-inflammatory cytokine 
(osteopontin) involved in the development of atherosclerosis (102). It has also been 
documented that PPARα, γ  and δ  reduce the cytokine-induced endothelial expression of 
adhesion molecules, e.g. VCAM-1 (21; 68; 121) along with reduction in macrophage 
infiltration within atherosclerotic plaques. 
Aims of study 
 
14 
AIMS OF STUDY 
The general purpose of this thesis work was to examine the effects of chronic administration of 
PPARα agonists on myocardial metabolism and ventricular function in obese/type 2 diabetic mice. 
Two different agonists were used; fenofibrate, which is used clinically to prevent hyperlipidemia 
and tetradecylthioacetic acid (TTA), a sulphur-containing FA with PPARα-activating potency. 
Both compounds were administered to the animals via the diet.  
The specific aims were to find out:  
(i) if fenofibrate and TTA were able to improve blood chemistry and reduce the 
predominant FA oxidation (and recover the capacity for glucose oxidation) in hearts 
from obese/diabetic mice  
(ii) if changes in metabolism following treatment with the compounds were associated with 
altered gene expression, as evaluated by real-time PCR measurements of the mRNA 
expression of selected PPARα-regulated genes 
(iii) if the two agonists had the potential to reduce myocardial oxygen consumption and 




METHODOLOGICAL CONSIDERATIONS   
Real-time quantitative PCR   
Gene expression analysis is of prime importance in the field of biological research, and 
among the methods which are being used for this purpose real-time qPCR has gained a lot 
of popularity because of its rapidity and sensitivity as compared to the traditional method 
for quantitative measurement of gene expression such as Northern blotting. Real-time 
qPCR is employed for both absolute and relative quantification of gene expression. We 
have used a relative quantification method by measuring the changes in Ct values for the 
specific genes of interest. Ct is fractional cycle number at which the PCR product crosses 
threshold of detection, which happens in the exponential phase of the amplification plot 
(see below). In relative mRNA quantification data is normalized against a housekeeping 
gene. This technique is especially suitable when small amounts of tissue or cells are 
available (46). The theory behind the mode of action of PCR was outlined by Kerry Mullis 
in 1983 (97; 98), although some pioneering work was also done by Gobind Khorana in 
1971, who described the basic principle of replicating DNA by using two primers. In the 
initial step complimentary DNA, synthesized from isolated mRNA by reverse transcription 
was channelled through different phases of real-time qPCR (denaturation, annealing and 
extension) along with primers and probes of the genes of interest, leading to an exponential 
increase in the number of copies of the gene of interest. The fluorescence signal in the 
exponential phase was captured by the qPCR detector and displayed by the software as an 
amplification plot. In gene expression analysis several parameters need to be controlled, 
such as the amount of starting material, sample handling, variation in the reverse 
transcription efficiencies and differences between tissues or cells in overall transcriptional 
activity (5). Various strategies have been employed to normalize these variations. For 




is not always representative of the mRNA fraction, because it consists predominantly of 
rRNA. In addition, it has been documented that various biological factors and drugs could 
effect the transcription of rRNA (130). Normalization of the expression of the target genes 
is a reliable method (108). When performing relative quantification of the expression of a 
target gene it is important to choose a suitable gene for use as a reference or housekeeping 
gene. Ideally, housekeeping genes should not vary in response to the experimental 
intervention but, unfortunately, despite being constant in a given cell-type or experimental 
condition, housekeeping genes can still vary (141). Therefore, instead of using one 
reference gene, we have used the geometric mean of the three best out of a selection of 5-6 
housekeeping genes, as recommended by Vandesompele et al. (141).   
 
Isolated working mouse heart model  
Hearts from small rodents are perfused ex vivo in mainly two different modes: (i) the 
Langendorff mode, in which the myocardium is perfused with a crystalloid buffer provided 
retrogradely to the aorta from a constant pressure head or a pump (constant flow) and (ii) 
the working heart mode, in which the left ventricle receives oxygenated buffer from a 
preload reservoir and ejects its content into an afterload column, which in turn creates the 
myocardial perfusion pressure (103). The Langendorff perfusion is named after Oskar 
Langendorff, who already in 1895 (80) described a method for measuring mechanical 
function of the isolated mammalian heart. In 1967 Neely developed the isolated working rat 
heart model (103) which is widely used for studying mechanical function and metabolic 
status of the rodent heart. Grupp et al. (54) for the first time examined functional 
parameters in an isolated, working mouse heart. These authors used mechanical resistance 
clamps to achieve a mean arterial pressure of 50 mmHg. Larsen et al. (81) developed the 




pressures, thereby achieving a stable working heart preparation. Functional and metabolic 
aspects of the working murine heart was also evaluated by de Windt et al (29). The major 
advantage with this model is that a number of experimental parameters like preload, 
afterload and heart rate, as well as the energy substrate supply, can be easily controlled 
(81). However it is important to remember that the ex vivo heart is devoid of any 
neurohumoral influence. In most studies the heart is perfused with a buffer containing only 
a few substrates (most often glucose ± FA). Despite these shortcomings, the isolated 
working mouse heart model has proven to be very useful, in particular because it allows 
simultaneous measurements of cardiac function and metabolism (103) in various transgenic 
models and mouse models of disease (90). 
  
Measurement of myocardial substrate utilization    
We measured rates of myocardial glucose and fatty acid oxidation by including trace 
amounts of [U-14C] glucose and [9, 10-3H] palmitate in the perfusion medium. 14CO2 and 
3H20, which were released by the oxidation of these substrates were trapped and used for 
calculation of the oxidation rates (3; 12; 14). However we did not measure the contribution 
of other energy substrates like lactate and ketone bodies, which can contribute to energy 
metabolism during exercise and starvation/diabetes, respectively (109).     
 
Measurement of myocardial oxygen consumption and cardiac work  
The oxygen tension of freshly oxygenated perfusion buffer, as well as of the coronary 
drainage, was measured by fibre-optic oxygen probes placed in the preload line and 
pulmonary trunck, respectively. Myocardial oxygen consumption (MVO2) was calculated 





Cardiac work was measured as pressure-volume area (PVA), using a miniaturized (1.2 and 
1.4 French) pressure-volume catheter, a technology which was introduced in our laboratory 
by Dr. Ole-Jakob How (62-64). Steady-state PVA and MVO2 values were obtained at 
different workloads by changing the pre- and afterload settings.  Unloaded MVO2 is the 
myocardial oxygen consumption at zero work, as determined by the y-intercept of the 
PVA:MVO2 relationship, and represents oxygen used for basal metabolism and excitation –
contraction coupling. Contractile efficiency is the inverse of the slope of the relationship 
(i.e. PVA-dependent increase in MVO2 divided by the PVA) (135; 136) 
 
PPAR ligands of interest  
Tetradecylthioacetic acid: TTA is a non-beta oxidizable fatty acid analogue with 
substitution of sulfur atom at position 3 in the carbon chain (Figure 5) and that is the reason 
why TTA cannot be oxidized itself (16). However, TTA leads to an increase in 
mitochondrial β-oxidation of FA (40; 55), probably related to the finding that 3-thia fatty 
acids caused production of megaperoxisomes and micromitochondria (15; 78) and 





Raspe has demonstrated that TTA can activate both PPAR α and PPAR γ in a concentration 
dependent manner (120). TTA feeding has caused proliferation of mitochondria not only in 
Fig 5: Chemical structure of Tetradecylthioacetic acid (TTA) showing substitution of sulfur 




the liver, (15; 78; 138) but also in skeletal muscle and heart (138). In NIH-3T3 cells from 
rodents it activates PPARα, PPARδ and PPARγ in a descending order (88). Short-term 
administration of TTA was associated with induction of hepatic CPT-I and CPT-II 
activities and FA oxidation (86; 87; 139). Thus, TTA by increasing the expression of genes 
involved in FA catabolism in liver resulted in decreased production of lipids from the liver 
and decreased plasma lipid levels (120). Besides its effects on lipid metabolism Muna et al. 
has documented antioxidant effects of TTA (99). Anti-inflammatory effects of TTA are 
also evident by its ability to attenuate TNFα-mediated endothelial cell activation (41). 
  
Fenofibrate:  This compound (Figure 6) is a derivative of fibric acid and has been used in 







Clofibrate and gemfibrozil became available in the United States in 1967 and1982 
respectively. Fenofibrate, the third generation fibric acid derivative was synthesized in 1975 
(129) and was introduced in clinical practice the same year (18). Today, fenofibrate is one 
of the most commonly used lipid-lowering drug worldwide with a wide range of effects on 
cholesterol and TG metabolism (10). The mechanism of action involves PPARα-mediated 
increase in hepatic FA oxidation, which consequently reduces the plasma concentration of 




lipids (56). In studies on type 2 diabetic (db/db) mice, long term fenofibrate administration 
improved hyperglycemia, insulin resistance, albuminuria and glomerular lesions (112). 
Fenofibrate treatment resulted in significant increases of plasma adiponectin levels in 
normal mice, as well as in cultured 3T3-L1 adipocytes (61), indicating that adipose tissue 
might also be a target organ for fibrates.  
 
K-111 (previously called BM 17.0744): K-111 (2,2-dicholoro-12-(p-chlorophenyl)-
dodecanoic acid) (Figure 7) belongs to a group of ω-substituted alkyl carboxylic acid  and 






K-111 is a newly developed insulin sensitizer and its anti-hyperinsulinemic and lipid-
lowering effects have been observed in rodents (115). It is a potent activator of PPARα with 
no activity against PPARγ (93; 145). A study comparing troglitazone with K-111 has 
revealed that the latter exerts a more potent hypoglycemic effect at lower doses (114). A 
similar hypoglycemic effect was associated with increased myocardial glucose oxidation 
along with a concomitant reduction in FA acid utilization was observed by our group in 
diabetic (db/db) mice treated with K-111 (1).
Fig.7: Molecular structure of K-111.  
Summary of results 
 
21 
SUMMARY OF RESULTS 
The peroxisome proliferator-activated receptors (PPARs) are a family of three ligand-
activated transcription factors, PPARα, PPARβ, and PPARγ. The clinical importance of the 
pathways controlled by these receptors has been demonstrated by the use of synthetic 
ligands for the receptors, e.g. fibrates (PPARα agonists) is used as a lipid-lowering agent in 
hyperlipidemic patients, while thiazolidinediones (PPARγ agonists) have beneficial effects 
on insulin sensitivity, as well as the lipid profile, in type 2 diabetes. The potential clinical 
benefit of PPARs on improving myocardial metabolism in type 2 diabetes is, however, less 
known.  
 
In paper I we examined the effects of long-term administration of the anti-lipidemic drug, 
fenofibrate, using diet-induced obese (DIO) mice. The plasma concentrations of fatty acids 
(FA), triacylglycerol (TG) and glucose was measured following four weeks treatment, as 
well as myocardial FA and glucose oxidation in isolated perfused hearts from these 
animals. In addition, we measured hepatic FA oxidation and biochemical activity and gene 
expression of metabolic enzymes in both liver and heart tissue. DIO mice, which were 
produced by feeding normal NMRI mice a sucrose-enriched diet, are considered a model of 
obesity or pre-diabetes. In line with this notion, the results showed that they have enlarged 
adipose tissue depots and exhibit increased plasma concentrations of lipids (FA and TG) 
and glucose, as well as increased myocardial FA oxidation and reduced glucose oxidation.  
 
Eleven to twelve weeks treatment with fenofibrate (0.1 % via the diet, w/w), however, led 
to reductions in the adipose tissue mass and plasma concentrations of lipids and glucose. 
The reduced lipid supply to the heart was associated with reduced rates of myocardial FA 
oxidation (and increased glucose oxidation), while hepatic FA oxidation was increased. 
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These changes in FA oxidation were accompanied by a significant decrease and increase in 
the activity of CPT-II and ACO activity in heart and liver, respectively. Moreover, 
examination of PPARα-regulated target genes showed increased expression of PDK4, CPT-
I, CPT-II, ACO and UCP2 in the liver, but no significant changes in cardiac tissue. Finally, 
hearts from DIO mice showed mechanical dysfunction, as indicated by lower baseline 
aortic flow and cardiac power than lean control hearts, and less functional recovery 
following ischemia-reperfusion. These defects were reversed by fenofibrate treatment. 
 
In conclusion, chronic treatment of DIO mice with fenofibrate resulted in normalization of 
the fuel supply to the heart and a concomitant improvement of the myocardial fuel 
utilization. The improvement in cardiac metabolism was associated with improved cardiac 
function and increased tolerance to ischemic stress.   
 
In paper II we examined the ability of fenofibrate to modify cardiac metabolism in diabetic 
(db/db) mice. Because the db/db mouse represents a rather severe degree of diabetes, we 
decided to use two different doses of the drug, a low dose of 0.1% and a high dose of 0.2%. 
Diabetic mice treated with K-111 (a PPARα agonist) served as positive controls, since 
previous studies from our own laboratory have demonstrated marked improvements in 
cardiac metabolism following treatment with this compound.  
 
Low-dose fenofibrate treatment resulted in reduced plasma concentration of FA and TG, 
but the concentration of glucose was not affected. On the other hand, both high-dose 
fenofibrate and K-111 treatment produced a drop in the plasma concentration of both lipids 
and glucose. Liver tissue from mice treated with fenofibrate and K-111 showed increased 
PPARα target gene expression in comparison to non-treated db/db mice, supporting the 
Summary of results 
 
23 
notion that the lipid-lowering effect of the compound was due to increased hepatic FA 
oxidation. As expected, the myocardial expression of PPARα target genes was up-regulated 
in hearts from db/db mice, but this response was prevented in hearts treated with fenofibrate 
and K-111. In line with previous results (1), treatment with K-111 caused a shift in 
myocardial metabolism in db/db hearts in favor of increased glucose oxidation. The same 
response was obtained after high-dose fenofibrate treatment, while myocardial substrate 
oxidation was unaffected by low-dose fenofibrate treatment. We did not observe any effect 
on the ventricular function following treatment, neither with (low or high-dose) fenofibrate 
nor K-111 (data not shown).  
 
In paper III we examined the effect of tetradecylthioacetic acid (TTA, a sulfur-containing 
fatty acid which has been characterized as a pan PPAR agonist) on plasma concentrations 
of energy substrates and myocardial metabolism in normal Balb/c mice. Animals were 
treated with TTA (0.5% w/w added to the diet) for 8 days. Thereafter, heart and liver were 
excised and used for measurement of mRNA expression of PPARα target genes. Another 
group of animals was used to study the effect of TTA on myocardial oxidation of FA and 
glucose, as well as its effect on the mechanical performance of the heart. Samples for 
measurement of plasma concentrations of lipids and glucose were obtained from all 
experimental groups. 
 
In line with previous results in rodents (59), the concentration of lipids was reduced in 
plasma from TTA-treated mice. At the same time, the expression of PPARα target genes 
(mRNA) was up-regulated both in liver and heart. TTA-treatment caused a 2.5-fold 
increase in myocardial FA oxidation (with a concomitant reduction in glucose oxidation), 
which matches the increased expression of PPARα target genes in the heart. It should be 
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noted, however, that the increase in myocardial FA oxidation occurred in the face of 
decreased levels of plasma lipids. Furthermore, there was no increase in myocardial FA 
oxidation in PPARα-null mice treated with TTA. Thus, it appears that the metabolic effects 
of TTA on the heart must be due to a direct stimulatory effect on cardiac PPARα, while the 
plasma lipid-lowering effect is most likely linked to activation of PPARα in the liver. TTA 
had no clear effect on the ventricular function. The TTA-induced increase in myocardial 
FA oxidation rate was associated with a near two-fold increase in unloaded MVO2, as well 
as decreased recovery of ventricular function following low-flow ischemia. 
  
We conclude that TTA, unlike other PPARα agonists, resulted in increased FA oxidation at 
the expense of glucose oxidation, increased expression of genes encoding FA metabolizing 
enzymes, increased myocardial oxygen consumption and reduced tolerance to ischemia-
reperfusion.  To our knowledge, TTA is the only compound having this effect on cardiac 
metabolism.  
 
In the last paper (paper IV) we tested the effect of chronic TTA treatment in the diabetic 
db/db mouse, which is a well accepted model of type 2 diabetes. We (4; 64) and others (22; 
23) have shown that hearts from db/db mice exhibit elevated rates of FA oxidation and 
reduced rates of glucose oxidation. Hearts from db/db mice also show increased unloaded 
MVO2 and reduced tolerance to ischemia (58; 64). Based on the findings of a direct 
stimulatory effect of TTA on FA oxidation in normal mouse hearts (paper III), however, we 
wondered whether TTA treatment would increase myocardial FA oxidation further in db/db 
hearts. Such an effect could have a dual outcome; it could compromise cardiac function by 
further increasing unloaded MVO2, but if TTA accelerates FA oxidation to a greater extent 
than FA uptake it could probably also correct the imbalance between fatty acid uptake and 
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oxidation and prevent myocardial lipotoxicity. Indeed, this assumption was supported by 
the fact that myocardial TG content was significantly reduced following TTA treatment. 
 
Type 2 diabetic (db/db) and non-diabetic (db/+) mice were treated with TTA for 8 days, 
and the same set of experiments as described for paper III were performed. Again we 
observed significant reductions in circulating FA, TG and glucose in db/db mice and 
increased mRNA expression of enzymes involved in the FA oxidation pathway in the liver. 
Myocardial FA oxidation was significantly increased in hearts from TTA-treated db/db 
mice, although the relative increase was considerably less than in hearts from control mice 
(75% vs 300%), and was not reflected in a further increase in unloaded MVO2. 
Surprisingly, TTA-mediated increase in myocardial fatty acid oxidation was not associated 
with increased expression of PPARα target genes in the diabetic mouse hearts.   
 
The most intriguing finding, however, was that hearts from TTA-treated db/db mice, in 






The cardiac metabolic phenotype of obese/diabetic mice is characterized by elevated FA 
oxidation and reduced glucose oxidation. In this thesis we have shown that chronic 
fenofibrate treatment of diet-induced obese (paper I) and type 2 diabetic mice (paper II) 
reduced plasma lipids and glucose and caused a switch in myocardial fuel selection towards 
higher glucose utilization at the expense of fatty acids. This change in myocardial 
metabolism was associated with improved ventricular function and improved tolerance to 
ischemia-reperfusion in DIO mice. Treatment of non-diabetic (paper III), as well as type 2 
diabetic mice (paper IV), with TTA was associated with accelerated myocardial FA 
oxidation, in spite of a reduced plasma supply of lipids. TTA also caused increased oxygen 
consumption and reduced tolerance to ischemia in hearts from non-diabetic mice. To our 
surprise, however, TTA treatment seemed to be protective in hearts from type 2 diabetic 
mice. 
 
Effect of fenofibrate on cardiac metabolism in obese mice and type 2 
diabetic mice 
In accordance with other studies (56; 70) , we found that fenofibrate treatment had a 
marked hypo-lipidemic effect and improved glucose homeostasis in diet induced obese 
(DIO) mice (paper I) and type 2 diabetic mice (paper II). Fenofibrate treatment also 
improved myocardial metabolism in these mice with increased oxidation of glucose at the 
expense of fatty acids.  
 
At a first glance, the changes in cardiac metabolism in response to fenofibrate were 
surprising, since PPARα regulates the expression of genes controlling both FA uptake and 




incubated with PPARα ligands, including endogenous ligands such as FA, show increased 
expression of PPARα target genes and increased FA oxidation (51; 140). Also, transgenic 
mice with cardiac-specific over-expression of PPARα show increased expression of 
PPARα target genes and increased FA oxidation (45). In line with this view one might 
argue that administration of a synthetic PPARα agonist should increase cardiac fatty acid 
oxidation further. On the other hand, we have previously shown that chronic treatment of 
type 2 diabetic mice (1; 2) with the PPARα ligand K-111 (previously called BM-17.0744) 
counteracts the high rates of myocardial palmitate oxidation which is otherwise found in 
these animals, a finding which was confirmed in paper II.  We suggest that in vivo 
treatment with PPARα ligands, by draining plasma lipids to the liver (increased hepatic β-
oxidation, paper I), will relieve the lipid load on the heart and result in adaptational changes 
in myocardial metabolism that are also maintained in the ex vivo setting. The lipid-lowering 
effect of fenofibrate could also be related to increased hepatic catabolism of VLDL 
triglyceride (mediated by lipoprotein lipase) and inhibition of the hepatic synthesis and 
secretion of VLDL (8). In support of this view fenofibrate treatment was found to markedly 
increase PPARα target genes in the liver, while the cardiac expression of these genes were 
either unchanged (paper I) or decreased (paper II). This is in accordance with Cook et al. 
(27), showing minor changes in PPARα target gene expression in extrahepatic tissues 
following administration of different PPARα ligands. Based on these findings, we suggest 
that the effects of fenofibrate on the heart should be regarded as a secondary response to the 
lipid-lowering effect of the compound. 
 
In paper II we found that the high dose of fenofibrate, but not the low dose, was able to 
shift the energy metabolism in hearts from db/db mice. The failure to improve myocardial 




resulted in reduced plasma FA and TG concentrations, without affecting the plasma glucose 
concentration. This combination of a low lipid and high glucose supply should by itself 
favour increased glucose oxidation in the heart, in line with the concept that the plasma 
supply is determining the metabolic phenotype of the heart. Apparently, the lack of effect 
on cardiac metabolism of low-dose fenofibrate is related to the persisting elevated glucose 
concentration. The high plasma glucose concentration during low-dose fenofibrate 
treatment will contribute to a near normal myocardial glucose uptake in the db/db mice 
despite insulin resistance (133). However, the glucose taken up is not properly utilized, and 
accumulated intracardiomyocyte glucose may increase flux through the hexosamine 
biosynthetic pathway (with increased N-acetyl-glucosamine production) (48) and influence 
gene transcription and post-translational alterations of proteins. These mechanisms could 
probably override the influence of substrate supply and prevent repair of cardiac 
metabolism during low-dose fenofibrate treatment. With high-dose fenofibrate both plasma 
FA and glucose concentrations were reduced, and in this case we also obtained a switch in 
myocardial fuel selection.  
 
Effect of fenofibrate treatment on cardiac function in obese and type 2 
diabetic mice  
Tabernero (137) found that chronic treatment of normal mice with fenofibrate reduced 
myocardial infarct size and improved post-ischemic contractile function in perfused hearts 
from these animals. In line with these results we found improved post-ischemic cardiac 
recovery in hearts from DIO mice (paper I). This response could possibly be a result of the 
fenofibrate-mediated metabolic switch in favor of glucose (and possibly reduced MVO2), 
although PPARα mediated anti-inflammatory effects, including suppression of vascular 





In hearts from DIO mice fenofibrate reversed the diet-induced ventricular dysfunction 
observed during normoxic/pre-ischemic conditions (paper I). However, we did not find any 
improvement in ventricular function in db/db mice (paper IV), despite hypo-lipidemic and 
hypoglycemic effects of the drug and normalization of myocardial metabolism (highest 
dose of fenofibrate). The db/db mouse represents a severe degree of diabetes, and 
irreversible structural changes (50) and a high oxidative stress (125) in this diabetic model 
might have prevented any functional benefit. In addition, the db/db mice were treated for 
only 4 weeks, compared to 10 weeks treatment of the DIO mice.     
 
Effects of TTA treatment on myocardial metabolism in normal and diabetic 
mice 
As mentioned above, the diabetic heart relies mainly on FA for energy production, and 
PPARs play a central role in the regulation of myocardial FA utilization. In accordance 
with previous studies, (88) we found that chronic TTA-treatment resulted in a significant 
reduction in the plasma concentration of glucose and lipids. The lipid-lowering effect was 
most likely secondary to PPARα-mediated hepatic uptake and oxidation of FA, as indicated 
a significant up-regulation of hepatic PPARα target genes. TTA-induced hepatic 
mitochondrial proliferation has also been suggested to play a central role in the regulation 
of plasma triglyceride concentration (15; 16; 139).  
 
Based on our previous results obtained with fenofibrate (paper I) and K-111 (1; 2) , a 
plasma profile with low lipid values should favor low rates of myocardial fatty acid 
oxidation. Again we were surprised to find the opposite, namely a markedly increased 




IV). One possible explanation for this phenomenon could be related to the uptake 
mechanism of TTA; during intestinal absorption TTA is probably incorporated in complex 
lipids during the reconversion of the products of lipid digestion, entering the lymph as very 
low density lipoproteins (VLDL) and chylomicrons. These particles are subsequently taken 
up in the blood and transported to the heart where the lipoprotein lipase at the coronary 
endothelium will provide for an efficient uptake of TTA into the myocardial cells, allowing    
direct PPARα-mediated effects on myocardial metabolism. In support of this view Asiedu 
et al (7) have reported higher concentrations of TTA in heart than in liver of TTA-treated 
Wistar rats. In addition, gene expression analysis showed significant up-regulation of 
PPARα target genes in hearts from TTA-treated Balb/c and db/+ mice (paper III and IV). 
On the other hand, there was no up-regulation of these genes in hearts from TTA- treated 
db/db mice. This observation could be related to the fact that PPAR α target genes are 
already up-regulated in diabetic myocardium, due to the increased supply of plasma lipids 
(44). In addition, any direct activation of PPARα by TTA was probably counteracted by the 
reduced supply of FA (the endogenous ligands of PPARα) as a result of the lipid-lowering 
effect of TTA.  
 
In this respect TTA was different from fenofibrate (and other PPARα agonists used in our 
group), for which the liver was the main target organ.  
 
Effect of TTA treatment on cardiac function in diabetic mice and non-
diabetic mice  
Increased myocardial FA oxidation in hearts from TTA-treated normal Balb/c and db/+ 
mice (papers III and IV) was associated with increased myocardial oxygen consumption 




reduced ischemic tolerance, while it was unchanged in db/+ hearts (paper IV). Hearts from 
TTA-treated db/db mice, on the other hand, showed increased post-ischemic functional 
recovery, despite increased FA oxidation. It is not difficult to understand that the strong 
increase in MVO2 in normal hearts in response to TTA will compromise the mechanical 
function of the heart, particularly in the reperfusion phase. The diabetic hearts, however, are 
probably adapted to a high FA utilization, and so the relatively moderate increase in 
myocardial FA oxidation in hearts from db/db mice in response to TTA treatment did not 
cause any further increase in unloaded MVO2. Probably, any TTA-mediated elevation of 
MVO2 in these hearts was masked by the inherently high MVO2 (64).    
 
The improved post-ischemic function in hearts from TTA-treated mice could probably be 
explained by TTA-mediated prevention of lipotoxicity. In the diabetic heart FA uptake 
exceeds the rate of oxidation, leading to accumulation of (toxic) lipid metabolites (147). 
Apparently, the increase in myocardial FA oxidation plus the decreased lipid supply in 
TTA-treated mice prevented this process. Thus, we observed a marked reduction in 
myocardial triglyceride content in TTA-treated diabetic hearts as compared to the non-
treated controls. Interestingly, Yu (149) has documented that PPARδ-mediated reduction in 
myocardial adiposity is vital for preventing diabetes-related myocardial dysfunction. In 
addition, TTA-mediated cardioprotection could be related to the reported antioxidant and 
anti-inflammatory effect of the compound (79); studies have shown that in vivo activation 
of PPARα is associated with induction of antioxidant enzymes such as catalase and 
superoxide dismutase (30; 66), which might be able to counteract the detrimental effects of 
oxidative stress during reperfusion. Finally, Wayman (142) reported that both PPARα and γ 






This thesis has demonstrated that fenofibrate can improve myocardial metabolism (slow 
down FA oxidation and increase glucose oxidation) in hearts from obese and type 2 
diabetic mice by altering the plasma substrate supply to the heart. In hearts from obese mice 
this metabolic improvement left the heart less vulnerable to ischemic stress. TTA treatment 
caused a marked increase in myocardial PPARα activity and FA oxidation. In non-diabetic 
hearts this increase in FA oxidation was associated with increased MVO2 and decreased 
tolerance to ischemia. In diabetic hearts, on the other hand, TTA treatment was 
cardioprotective. Taken together, these results show that PPARα agonists can be useful 
tools for modifying cardiac metabolism, with potential improvements in cardiac function, in 
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Primer and probe sequences used in real-time quantitative RT-PCR 
 
 
Gene name Primer/probe sequence (5’-3’) 
PPARα target genes 
Muscle carnitine palmityol transferase I 
mcpt1 Forward ATG-ATG-TAT-CGC-CGC-AAA-CT 
 Reverse ATC-TGG-TAG-GAG-CAC-ATGG-GT 
 Probe TCA-AGC-CGG-TAA-TGG-CAC-TGG-CAC-TGG-G 
Liver carnitine palmityol transferase 1 
lcpt1 Forward AAA-CCC-ACC-AGG-CTA-CAG-TG 
 Reverse GGC-ACT-GCT-TAG-GGA-TGT-GT 
 Probe # 2 in Roche Universal ProbeLibrary 
PDH-kinase 
pdk4 Forward TTC-ACA-CCT-TCA-CCA-CAT-GC 
 Reverse AAA-GGG-CGG-TTT-TCT-TGA-TG 
 Probe CGT-GGC-CCT-CAT-GGC-ATG-GCA-TTC-TTG 
Uncoupling protein 3 
ucp3 Forward TAC-CCA-ACC-TTG-GCT-AGA-CG 
 Reverse GCC-TGG-CAA-TCT-TTT-GCT-T 
 Probe # 69 in Roche Universal ProbeLibrary 
Uncoupling protein 2 
ucp2 Forward ACA-GCC-TTC-TGC-ACT-CCT-G 
 Reverse GGC-TGG-GAG-ACG-AAA-CAC-T 
 Probe # 2 in Roche Universal ProbeLibrary 
Cytosolic thioesterase I 
cte1 Forward ACC-CCC-TGT-GAC-TAT-CCT-GAG 
 Reverse TTC-TAC-CAG-AGG-GCT-TTG-CA 
 Probe AGC-ATC-TAC-AAC-ATC-CTT-GAG-GCC-ATC-CT 
Mitochonsdrial thioesterase I 
mte1 Forward TGG-GAA-CAC-CAT-CTC-CTA-CAA 
 Reverse CCA-CGA-CAT-CCA-AGA-GAC-CA 
 Probe AGA-CTA-TAC-CCC-CTG-TGT-CCC-TTG-TGA-GAA 
Medium-chain acyl CoA dehydrogenase 
mcad Forward TGG-CAT-ATG-GGT-GTA-CAG-GG 
 Reverse CCA-AAT-ACT-TCT-TCT-TCT-GTT-GAT-CA 




Gene name                  Primer/probe sequence (5’-3’) 
Housekeeping genes 
Glyceraldehyd-3-phosphate dehydrogenase 
gapdh Forward TCA-CCA-CCA-TGG-AGA-AGG-C 
 Reverse GCT-AAG-CAG-TTG-GTG-GTG-CA 
 Probe ATG-CCC-CCA-TGT-TTG-TGA-TGG-GTG-T 
Cyclophilin 
cyclo Forward CTG-ATG-GCG-AGC-CCT-TG 
 Reverse TCT-GCT-GTC-TTT-GGA-ACT-TTG-TC 
 Probe CGC-GTC-TGC-TTC-GAG-CTG-TTT-GCA 
Hypoxanthine-guanine phosphoribosyl transferase 
hprt Forward TCC-TCC-TCA-GAC-CGC-TTT-T 
 Reverse CCT-GGT-TCA-TCA-TCG-CTA-ATC 
 Probe # 95 in Roche Universal ProbeLibrary 
Succinate dehydrogenase complex subunit A 
sdha Forward TGT-TCA-GTT-CCA-CCC-CAC-A 
 Reverse CAC-GAC-ACC-CTT-CTG-TGA-TG 
 Probe # 71 in Roche Universal ProbeLibrary 
Acidic ribosomal phosphoprotein 
arbp Forward CGA-GAA-GAC-CTC-CTT-CTT-CCA 
 Reverse TTA-TCA-GCT-GCA-CAT-CAC-TCA-G 
 Probe # 105 Roche 
Hydroxymethylbilane synthase 
hmbs Forward GCT-CAG-ATA-GCA-TGC-AAG-AGA-CTA 
 Reverse TCT-GGA-CCA-TCT-TCT-TGC-TGA 
 Probe # 49 in Roche Universal ProbeLibrary 
 
